Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)

TP53 mutant head and neck squamous cell carcinoma (HNSCC) patients exhibit poor clinical outcomes with 50–60% recurrence rates in advanced stage patients. In a recent phase II clinical trial, adjuvant therapy with everolimus (mTOR inhibitor) significantly increased 2-year progression-free survival i...

Descripción completa

Detalles Bibliográficos
Autores principales: Alam, Md Maksudul, Fermin, Janmaris Marin, Knackstedt, Mark, Noonan, Mackenzie J., Powell, Taylor, Goodreau, Landon, Daniel, Emily K., Rong, Xiaohua, Moore-Medlin, Tara, Khandelwal, Alok R., Nathan, Cherie-Ann O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901561/
https://www.ncbi.nlm.nih.gov/pubmed/36745547
http://dx.doi.org/10.18632/oncotarget.28355

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901561/
https://www.ncbi.nlm.nih.gov/pubmed/36745547
http://dx.doi.org/10.18632/oncotarget.28355

Ejemplares similares